Role of Protein Kinase C in Diabetic Complications

Published: November 5, 2019


  • Simran
  • Amarjot Kaur Grewal
  • Sandeep Arora
  • Thakur Gurjeet Singh
Diabetes mellitus, Hyperglycemia, PKC, Microvascular complications, PKC inhibitors


Diabetes is the most common and systemic disorder associated with hyperglycemia which is the significant factor in the development of micro- and macrovascular changes. Many mechanistic approaches i.e. activation of Protein kinase C, glycation end products production, hexosamine pathway and polyol pathway induce cellular damage and lead to the development of diabetic complications like nephropathy, neuropathy, retinopathy, and myopathy. One of the adverse effects of long-lasting hyperglycemia is activation of PKC (intracellular signaling enzyme) and has become a field of great research interest. Hence, in this review special emphasis is placed on microvascular complications which are due to activation of PKC. Clinical trials have also been conducted using selective PKC inhibitors and have shown positive results against hyperglycemia.


Adibhatla, R.M., Dempsey, R. and Hatcher, J.F. (2008). Integration of cytokine biology and lipid metabolism in stroke. Frontiers in bioscience: a journal and virtual library, 13, 1250.

Af Gennas, G.B., Talman, V., Aitio, O., Ekokoski, E., Finel, M., Tuominen, R.K. and Yli-Kauhaluoma, J. (2009). Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. Journal of medicinal chemistry, 52(13), 3969-3981.

Aiello, L.P. (2002). The potential role of PKC β in diabetic retinopathy and macular edema. Survey of ophthalmology, 47, S263-S269.

Aiello, L.P., Clermont, A., Arora, V., Davis, M.D., Sheetz, M.J., Bursell, S.E. (2006). Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Investigative ophthalmology & visual science. 2006 Jan 1, 47(1), 86-92.

American Diabetes Association (2005). The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005 Jul 1, 54(7), 2188-2197.

Argoff, C.E., Cole, B.E., Fishbain, D.A. and Irving, G.A. (2006). Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. In Mayo Clinic Proceedings. 81(4), S3-S11. Elsevier.

Arimura, T., Hayashi, T., Terada, H., Lee, S.Y., Zhou, Q., Takahashi, M., Ueda, K., Nouchi, T., Hohda, S., Shibutani, M. and Hirose, M. (2004). A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. Journal of Biological Chemistry, 279(8), 6746-6752.

Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A. and Nagler, A. (2008). Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research, 14(10), 3044-3051.

Boone, T.K. (2013). liposomal formulation of rational combination of bioactive lipids for the treatment of leukemia (doctoral dissertation)

Brooks, B., Delaney-Robinson, C., Molyneaux, L. and Yue, D.K. (2008). Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C β inhibitor, ruboxistaurin. Journal of diabetes and its complications, 22(2), 88-95.

Caldwell, R.B., Bartoli, M., Behzadian, M.A., El‐Remessy, A.E., Al‐Shabrawey, M., Platt, D.H. and Caldwell, R.W. (2003). Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.   Diabetes/metabolism research and reviews, 19(6), 442-455.

Cameron, N.E., Gibson, T.M., Nangle, M.R. and Cotter, M.A. (2005). Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Annals of the New York Academy of Sciences, 1043(1), 784-792.

Carrie, D. (2014). Transcriptional and Post-translational Regulation of Cytosolic Carbonic Anhydrase in Rainbow Trout (Oncorhynchus mykiss) and Zebrafish (Danio rerio) (Doctoral dissertation, Université d’Ottawa/University of Ottawa).

Chua, D.T., Sham, J.S. and Au, G.K. (2005). A phase II study of docetaxel and cisplatin as first-line chemotherapy in                patients  with        metastatic             nasopharyngeal carcinoma. Oral oncology, 41(6), 589-595.

Dirks, J., Remuzzi, G., Horton, S., Schieppati, A. and Rizvi, S.A.H. (2006). Diseases of the kidney and the urinary system. Disease control priorities in developing countries, 2, 695-706.

Evcimen, N.D. and King, G.L. (2007). The role of protein kinase C activation and the vascular complications of diabetes. Pharmacological research, 55(6), 498-510.

Geraldes, P. and King, G.L. (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation research, 106(8), 1319-1331.

Gonçalves, C.M. (2013). Scavenger receptor cysteine- rich proteins on the cross-roads between innate and adaptive immunity.

Joy, S.V., Scates, A.C., Bearelly, S., Dar, M., Taulien, C.A., Goebel, J.A., Cooney, M.J. (2005). Ruboxistaurin, a protein kinase C β inhibitor, as an emerging treatment for diabetes microvascular complications. Annals of Pharmacotherapy, 39(10), 1693-1699.

Karasu, Ç. (2010). Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. The open cardiovascular medicine journal, 4, 240.

Kaschina, E. and Unger, T. (2003). Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood pressure, 12(2), 70-88.

Khera, T.K. (2006). Mesangial cell apoptosis and phagocytosis: the role of glucoseand transforming growth factor β-1. Cardiff University (United Kingdom).

Marsigliante, S., Muscella, A., Greco, S., Elia, M.G., Vilella, S. and Storelli, C. (2001). Na+/K+ ATPase activity inhibition and isoform-specific translocation of protein kinase C following angiotensin II administration in isolated eel enterocytes. Journal of endocrinology, 168(2), 339-346.

Martin, A., Komada, M.R. and Sane, D.C. (2003). Abnormal angiogenesis in diabetes mellitus. Medicinal research reviews, 23(2), 117-145.

Nagpal, M., Nagpal, K. and Nagpal, P.N. (2007). A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian journal of ophthalmology, 55(6). 437-439.

Naito, J., Koretsune, Y., Sakamoto, N., Shutta, R., Yoshida, J., Yasuoka, Y., Yoshida, S., Chin, W., Kusuoka, H. and Inoue, M. (2001). Transmural heterogeneity of myocardial integrated backscatter in diabetic patients without overt cardiac disease. Diabetes research and clinical practice, 52(1), 11-20.

Nakamura, J., Kato, K., Hamada, Y., Nakayama, M., Chaya, S., Nakashima, E., Naruse, K., Kasuya, Y., Mizubayashi, R., Miwa, K. and Yasuda, Y. (1999). A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes, 48(10), 2090-2095.

Nassar, H., Kantarci, A. and Van Dyke, T.E. (2007). Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation. Periodontology, 2000, 43(1), 233-244.

Nilsson, D. (2016). Forkhead Genes in Adipocytes and Podocytes. Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg.

Nishikawa, T., Edelstein, D., Brownlee, M. (2000). The missing link: a single unifying mechanism for diabetic complications. Kidney International, 58(S77), S26-S30.

Noh, H. and King, G.L. (2007). The role of protein kinase C activation in diabetic nephropathy. Kidney International, 72(S106), S49-S53.

Picchi, A., Capobianco, S., Qiu, T., Focardi, M., Zou, X., Cao, J.M. and Zhang, C. (2010). Coronary microvascular dysfunction in diabetes mellitus: a review. World journal of cardiology, 2(11), 377-390.

Prabhakar, S.S. (2004). Role of nitric oxide in diabetic nephropathy. Seminars in nephrology, 24(4), 333-344.

Sakata, K., Kondo, T., Mizuno, N., Shoji, M., Yasui, H., Yamamori, T., Inanami, O., Yokoo, H., Yoshimura, N. and Hattori, Y. (2015). Roles of ROS and PKC-βII in ionizing radiation-induced eNOS activation in human vascular endothelial cells. Vascular pharmacology, 70, 55-65.

Schramm, T.K., Gislason, G.H., Vaag, A., Rasmussen, J.N., Folke, F., Hansen, M.L., Fosbøl, E.L., Køber, L., Norgaard, M.L., Madsen, M. and Hansen, P.R. (2012). Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European heart journal, 32(15), 1900-1908.

Sheetz, M.J. and King, G.L. (2002). Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. Jama, 288(20), 2579-2588.

Shen, G.X., Way, K.J., Jacobs, J.R., King, G.L. (2003). Applications of inhibitors for protein kinase C and their isoforms. Protein Kinase C Protocols, 233, 397-422.

Spiegel, S., Foster, D. and Kolesnick, R. (1996). Signal transduction through lipid second messengers. Current opinion in cell biology, 8(2), 159-167.

Tonneijck, L., Muskiet, M.H., Smits, M.M., Van Bommel, E.J., Heerspink, H.J., Van Raalte, D.H. and Joles, J.A. (2017). Glomerular hyperfiltration in  diabetes: mechanisms,        clinical   significance, and treatment. Journal of the American Society of Nephrology, 28(4), 1023-1039.

Tripathi, B.K. and Srivastava, A.K. (2006). Diabetes mellitus: Complications and therapeutics. Medical Science Monitor, 12(7), RA130-147.

Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M. and Telser, J. (2007). Free radicals and antioxidants in   normal   physiological   functions   and   human disease. The international journal of biochemistry & cell biology, 39(1), 44-84.

Vinik, A. (2005). The protein kinase C-β inhibitor, ruboxistaurin,            for           the          treatment              of diabetic microvascular complications. Expert opinion on investigational drugs, 14(12), 1547-1559.

Wang, Y., Yin, O.Q., Graf, P., Kisicki, J.C., Schran, H. (2008). Dose and time dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. The Journal of Clinical Pharmacology, 48(6), 763-75.

Wang, Y., Yang, H., Liu, H., Huang, J., Song, X. (2009). Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC cancer, 9(1), 174.

Williamson, J.R., Chang, K., Frangos, M., Hasan, K.S., Ido, Y., Kawamura, T., Nyengaard, J.R., van Den Enden, M., Kilo, C. and Tilton, R.G. (1993). Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 42(6), 801-813.

How to Cite

Simran, Amarjot Kaur Grewal, Sandeep Arora and Thakur Gurjeet Singh. Role of Protein Kinase C in Diabetic Complications. J. Pharm. Technol. Res. Manag.. 2019, 07, 87-95
Role of Protein Kinase C in Diabetic Complications

Current Issue

ISSN Print2321-2217
ISSN Online2321-2225
RNI No.CHAENG/2013/50088
OA Policy

Publisher's policy of the journal at Sherpa UK for the submitted, accepted, and published articles. Click OAPolicy

Plan-S Compliance

To check compliance, one has to use the Journal Check Tool (JCT). This tool provided by cOAlition S (European funders) for the researchers (fundee) to check the compliance with the journal.

Recommend journal to your library

You can recommend the journal being a researcher or faculty member to your library. We will post a copy of the Journal to your library on your behalf at free of cost.
Click here: Recommend Journal

Preprint Arxiv Submission

The authors are encouraged to submit the author’s copy (preprint) to appropriate preprint archives e.g. and/or on or institutional repositories (e.g., D Space) before paper acceptance by the editor of Journal. After publications of the paper author(s) should mention the citation information, title and abstract along with DOI number of the publication carefully on the required page of the depository(ies).

Contact: Phone: +91-172-2741000, +91-172-4691800

Email :;

Abstract and Indexing


This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles in Journal of Nuclear Physics, Material Sciences, Radiation and Applications (J. Nucl. Phy. Mat. Sci. Rad. A.) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.

View Legal Code of the above-mentioned license,

View Licence Deed here

Creative Commons License

Journal of Nuclear Physics, Material Sciences, Radiation and Applications by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at